Search

Your search keyword '"Meers, Stef"' showing total 6 results
Start Over Author "Meers, Stef" Publisher american society of hematology
6 results on '"Meers, Stef"'

1. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

Author

Pagano, Livio, primary, Salmanton-García, Jon, additional, Marchesi, Francesco, additional, Blennow, Ola, additional, Gomes da Silva, Maria, additional, Glenthøj, Andreas, additional, van Doesum, Jaap, additional, Bilgin, Yavuz M., additional, López-García, Alberto, additional, Itri, Federico, additional, Nunes Rodrigues, Raquel, additional, Weinbergerová, Barbora, additional, Farina, Francesca, additional, Dragonetti, Giulia, additional, Berg Venemyr, Caroline, additional, van Praet, Jens, additional, Jaksic, Ozren, additional, Valković, Toni, additional, Falces-Romero, Iker, additional, Martín-Pérez, Sonia, additional, Jiménez, Moraima, additional, Dávila-Valls, Julio, additional, Schönlein, Martin, additional, Ammatuna, Emanuele, additional, Meers, Stef, additional, Delia, Mario, additional, Stojanoski, Zlate, additional, Nordlander, Anna, additional, Lahmer, Tobias, additional, Imre Pinczés, László, additional, Buquicchio, Caterina, additional, Piukovics, Klára, additional, Ormazabal-Vélez, Irati, additional, Fracchiolla, Nicola, additional, Samarkos, Michail, additional, Méndez, Gustavo-Adolfo, additional, Hernández-Rivas, José-Ángel, additional, Espigado, Ildefonso, additional, Cernan, Martin, additional, Petzer, Verena, additional, Lamure, Sylvain, additional, di Blasi, Roberta, additional, Marques de Almedia, Joyce, additional, Dargenio, Michelina, additional, Biernat, Monika M., additional, Sciumè, Mariarita, additional, de Ramón, Cristina, additional, de Jonge, Nick, additional, Batinić, Josip, additional, Aujayeb, Avinash, additional, Marchetti, Monia, additional, Fouquet, Guillemette, additional, Fernández, Noemí, additional, Zambrotta, Giovanni, additional, Sacchi, Maria Vittoria, additional, Guidetti, Anna, additional, Demirkan, Fatih, additional, Prezioso, Lucia, additional, Ráčil, Zdeněk, additional, Nucci, Marcio, additional, Mladenović, Miloš, additional, Liévin, Raphaël, additional, Hanáková, Michaela, additional, Gräfe, Stefanie, additional, Sili, Uluhan, additional, Machado, Marina, additional, Cattaneo, Chiara, additional, Adžić-Vukičević, Tatjana, additional, Verga, Luisa, additional, Labrador, Jorge, additional, Rahimli, Laman, additional, Bonanni, Matteo, additional, Passamonti, Francesco, additional, Pagliuca, Antonio, additional, Corradini, Paolo, additional, Hoenigl, Martin, additional, Koehler, Philipp, additional, Busca, Alessandro, additional, and Cornely, Oliver A., additional

Published
2022
Full Text
View/download PDF

2. Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)

Author

Zeidan, Amer M., primary, Ando, Kiyoshi, additional, Rauzy, Odile, additional, Turgut, Mehmet, additional, Wang, Ming-Chung, additional, Cairoli, Roberto, additional, Hou, Hsin-An, additional, Kwong, Yok-Lam, additional, Arnan Sangerman, Montserrat, additional, Meers, Stef, additional, Pullarkat, Vinod A., additional, Santini, Valeria, additional, Malek, Kamel, additional, Kiertsman, Flavia, additional, Lyu, Jiaying, additional, Marques Ramos, Pedro, additional, Fenaux, Pierre, additional, Miyazaki, Yasushi, additional, and Platzbecker, Uwe, additional

Published
2022
Full Text
View/download PDF

3. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

Author

Gilead Sciences, Pagano, Livio, Salmanton-García, Jon, Marchesi, Francesco, Blennow, Ola, Gomes Da Silva, María, Glenthøj, Andrea, Doesum, Jaap van, Bilgin, Yavuz M., López-García, Alberto, Itri, Federico, Nunes-Rodrigues, Raquel, Farina, Francesca, Dragonetti, Giulia, Berg Venemyr, Caroline, Praet, Jens van, Jakšić, Ozren, Valković, Toni, Falces-Romero, Iker, Martín-Pérez, Sonia, Jiménez, Moraima, Dávila, Julio, Schönlein, Martin, Ammatuna, Emanuele, Meers, Stef, Delia, Mario, Stojanoski, Zlate, Nordlander, Anna, Lahmer, Tobias, Pinczés, László Imre, Buquicchio, Caterina, Piukovics, Klára, Ormazabal-Vélez, Irati, Fracchiolla, Nicola S., Samarkos, Michail, Méndez, Gustavo-Adolfo, Hernández-Rivas, José Ángel, Espigado, Ildefonso, Čerňan, Martin, Petzer, Verena, Lamure, Sylvain, Blasi, Roberta di, Marques de Almedia, Joyce, Dargenio, Michelina, Biernat, Monika, Sciumè, Mariarita, Ramón, Cristina de, Jonge, Nick de, Batinić, Josip, Aujayeb, Avinash, Marchetti, Monia, Fouquet, Guillemette, Fernández, Noemí, Zambrotta, Giovanni, Sacchi, Maria Vittoria, Guidetti, Anna, Demirkan, Fatih, Prezioso, Lucia, Ráčil, Zdeněk, Nucci, Marcio, Mladenovic, Milos, Lievin, Raphaël, Hanakova, Michaela, Gräfe, Stefanie, Sili, Uluhan, Machado, Marina, Cattaneo, Chiara, Adžić-Vukičević, Tatjana, Verga, Luisa, Labrador, Jorge, Rahimli, Laman, Bonanni, Matteo, Passamonti, Francesco, Pagliuca, Antonio, Corradini, Paolo, Hoenigl, Martin, Koehler, Philipp, Busca, Alessandro, Cornely, Oliver A., Gilead Sciences, Pagano, Livio, Salmanton-García, Jon, Marchesi, Francesco, Blennow, Ola, Gomes Da Silva, María, Glenthøj, Andrea, Doesum, Jaap van, Bilgin, Yavuz M., López-García, Alberto, Itri, Federico, Nunes-Rodrigues, Raquel, Farina, Francesca, Dragonetti, Giulia, Berg Venemyr, Caroline, Praet, Jens van, Jakšić, Ozren, Valković, Toni, Falces-Romero, Iker, Martín-Pérez, Sonia, Jiménez, Moraima, Dávila, Julio, Schönlein, Martin, Ammatuna, Emanuele, Meers, Stef, Delia, Mario, Stojanoski, Zlate, Nordlander, Anna, Lahmer, Tobias, Pinczés, László Imre, Buquicchio, Caterina, Piukovics, Klára, Ormazabal-Vélez, Irati, Fracchiolla, Nicola S., Samarkos, Michail, Méndez, Gustavo-Adolfo, Hernández-Rivas, José Ángel, Espigado, Ildefonso, Čerňan, Martin, Petzer, Verena, Lamure, Sylvain, Blasi, Roberta di, Marques de Almedia, Joyce, Dargenio, Michelina, Biernat, Monika, Sciumè, Mariarita, Ramón, Cristina de, Jonge, Nick de, Batinić, Josip, Aujayeb, Avinash, Marchetti, Monia, Fouquet, Guillemette, Fernández, Noemí, Zambrotta, Giovanni, Sacchi, Maria Vittoria, Guidetti, Anna, Demirkan, Fatih, Prezioso, Lucia, Ráčil, Zdeněk, Nucci, Marcio, Mladenovic, Milos, Lievin, Raphaël, Hanakova, Michaela, Gräfe, Stefanie, Sili, Uluhan, Machado, Marina, Cattaneo, Chiara, Adžić-Vukičević, Tatjana, Verga, Luisa, Labrador, Jorge, Rahimli, Laman, Bonanni, Matteo, Passamonti, Francesco, Pagliuca, Antonio, Corradini, Paolo, Hoenigl, Martin, Koehler, Philipp, Busca, Alessandro, and Cornely, Oliver A.

Abstract

Limited data are available on breakthrough COVID-19 in patients with hematologic malignancy (HM) after anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Adult patients with HM, ≥1 dose of anti-SARS-CoV-2 vaccine, and breakthrough COVID-19 between January 2021 and March 2022 were analyzed. A total of 1548 cases were included, mainly lymphoid malignancies (1181 cases, 76%). After viral sequencing in 753 cases (49%), the Omicron variant was prevalent (517, 68.7%). Most of the patients received ≤2 vaccine doses before COVID-19 (1419, 91%), mostly mRNA-based (1377, 89%). Overall, 906 patients (59%) received COVID-19-specific treatment. After 30-day follow-up from COVID-19 diagnosis, 143 patients (9%) died. The mortality rate in patients with the Omicron variant was 7.9%, comparable to other variants, with a significantly lower 30-day mortality rate than in the prevaccine era (31%). In the univariable analysis, older age (P < .001), active HM (P < .001), and severe and critical COVID-19 (P = .007 and P < .001, respectively) were associated with mortality. Conversely, patients receiving monoclonal antibodies, even for severe or critical COVID-19, had a lower mortality rate (P < .001). In the multivariable model, older age, active disease, critical COVID-19, and 2-3 comorbidities were correlated with a higher mortality, whereas monoclonal antibody administration, alone (P < .001) or combined with antivirals (P = .009), was protective. Although mortality is significantly lower than in the prevaccination era, breakthrough COVID-19 in HM is still associated with considerable mortality. Death rate was lower in patients who received monoclonal antibodies, alone or in combination with antivirals.

Published
2022

4. Real-Life Outcomes of Ponatinib Treatment in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Data from a Nationwide Belgian Registry

Author

Devos, Timothy, primary, Havelange, Violaine, additional, Theunissen, Koen, additional, Meers, Stef, additional, Benghiat, Fleur Samantha, additional, Gadisseur, Alain, additional, Vanstraelen, Gaëtan, additional, André, Marc, additional, Bailly, Benjamin, additional, Granacher, Nikki, additional, Lewalle, Philippe, additional, De Becker, Ann, additional, Van Eygen, Koen, additional, Lejeune, Marie, additional, Deeren, Dries, additional, Nifosi, Gianfilippo, additional, Triffet, Agnes, additional, Vrelust, Inge, additional, Bekaert, Julie, additional, Beck, Michael, additional, and Selleslag, Dominik, additional

Published
2019
Full Text
View/download PDF

5. Efficacy and Safety of Ponatinib in CML and Ph+ ALL Patients in Real-World Clinical Practice: Data from a Belgian Registry

Author

Devos, Timothy, primary, Theunissen, Koen, additional, Benghiat, Fleur Samantha, additional, Gadisseur, Alain, additional, Meers, Stef, additional, Selleslag, Dominik, additional, Vanstraelen, Gaëtan, additional, Zachée, Pierre, additional, André, Marc, additional, Lewalle, Philippe, additional, Janssen, Mia, additional, Schots, Rik, additional, Van Eygen, Koen, additional, Kentos, Alain, additional, Lejeune, Marie, additional, Triffet, Agnes, additional, Vrelust, Inge, additional, Kuipers, Carolina, additional, and Havelange, Violaine, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results